[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639502":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":76,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MRI-guided SBRT","EXPERIMENTAL","Patients with oligometastatic peritoneal carcinomatosis will receive MRI-guided stereotactic body radiotherapy (MRIgSBRT) delivered with a hybrid MRI-linear accelerator using online adaptive planning and real-time tumor tracking. Treatment dose will range from 30 to 50 Gy in 5 fractions according to clinical judgment and organ-at-risk constraints.",[13],"Device: MRI-guided stereotactic body radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","MRI-guided stereotactic body radiotherapy","Patients will receive MRI-guided stereotactic body radiotherapy (MRIgSBRT) delivered using a hybrid MRI-linear accelerator with online adaptive planning and real-time tumor tracking. Treatment will consist of 30-50 Gy delivered in 5 fractions according to clinical judgment, target characteristics, and organ-at-risk constraints. Daily adaptive replanning may be performed to account for anatomical changes and optimize dose delivery in patients with oligometastatic peritoneal carcinomatosis.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Luca Boldrini","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+390630158195","luca.boldrini@policlinicogemelli.it",[31],{"facility":32,"status":20,"city":33,"state":20,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Gemelli ART (Advanced Radiation Therapy)-Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Roma","000168","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],11.10642,44.99364,{"lat":41,"lon":40},[44,46],{"name":23,"role":27,"phone":45,"phoneExt":20,"email":29},"+390630155701",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100639502","phase-2-mri-guided-adaptive-radiotherapy-for-limited-peritoneal-metastases-maracas-trial-100639502",false,"NCT07593261","MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).","MARACAS: A Phase II Trial of MRI-guided Adaptive Stereotactic RAdiotherapy in oligometastatiC Patients With Peritoneal Spread.","MARACAS","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG performance status 0-2\n* Life expectancy ≥6 months\n* Up to 5 MRI-visible peritoneal nodules\n* PCI ≤20\n* No prior radiotherapy in the same abdominal region within 6 months\n* Signed informed consent\n* History of prior CRS and\u002For HIPEC\n\nExclusion Criteria:\n\n* Diffuse peritoneal carcinomatosis\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (those conditions should be discussed with the patient before registration in the trial)\n* Significant comorbidities (such as: severe cardiac or coagulative disease, moderate or severe\n* restrictive\u002Fobsiructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment.\n* Pregnancy or breastfeeding\n* MRI contraindications (e.g., pacemaker, severe claustrophobia)","ALL","18 Years",{"count":60,"type":61},34,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This prospective phase II study evaluates the efficacy and safety of MRI-guided stereotactic body radiotherapy (MRIgSBRT) in patients with oligometastatic peritoneal carcinomatosis from gastrointestinal or gynecological tumors. Eligible patients with up to 5 MRI-visible peritoneal lesions and PCI ≤20 will be treated with MRIgSBRT using a hybrid MRI-linear accelerator with online adaptive planning and real-time tumor tracking.\n\nThe primary endpoint is radiologic response rate according to RECIST 1.1 criteria. Secondary endpoints include overall survival, progression-free survival, local control, chemotherapy-free survival, and treatment-related toxicity. The study aims to assess MRIgSBRT as a safe and non-invasive treatment option for selected patients with limited peritoneal metastatic disease.",[67,68,69],"Peritoneal Carcinomatosis","Oligometastatic Disease","Peritoneal Metastases",[71,72,73,74,75],"MRI-guided radiotherapy","Stereotactic body radiotherapy","Peritoneal carcinomatosis","Peritoneal metastases","Online adaptive radiotherapy","NOT_YET_RECRUITING","2026-05-12",{"date":79,"type":80},"2026-05-18","ACTUAL",{"date":82,"type":61},"2026-07",{"date":84,"type":61},"2032-07",{"name":5,"class":6},1]